BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 35279121)

  • 1. Pedigree investigation, clinical characteristics, and prognosis analysis of haematological disease patients with germline TET2 mutation.
    Wu X; Deng J; Zhang N; Liu X; Zheng X; Yan T; Ye W; Gong Y
    BMC Cancer; 2022 Mar; 22(1):262. PubMed ID: 35279121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
    Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
    Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inherited thrombocytopenia and platelet disorders with germline predisposition to myeloid neoplasia.
    Galera P; Dulau-Florea A; Calvo KR
    Int J Lab Hematol; 2019 May; 41 Suppl 1():131-141. PubMed ID: 31069978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.
    Lin TL; Nagata Y; Kao HW; Sanada M; Okuno Y; Huang CF; Liang DC; Kuo MC; Lai CL; Lee EH; Shih YS; Tanaka H; Shiraishi Y; Chiba K; Lin TH; Wu JH; Miyano S; Ogawa S; Shih LY
    Haematologica; 2014 Jan; 99(1):28-36. PubMed ID: 23996483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis.
    Guo Z; Zhang SK; Zou Z; Fan RH; Lyu XD
    Leuk Res; 2017 Jul; 58():102-107. PubMed ID: 28521175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Germline TET2 Mutations in Two Unrelated Patients with Autoimmune Lymphoproliferative Syndrome-Like Phenotype and Hematologic Malignancy.
    López-Nevado M; Ortiz-Martín J; Serrano C; Pérez-Saez MA; López-Lorenzo JL; Gil-Etayo FJ; Rodríguez-Frías E; Cabrera-Marante O; Morales-Pérez P; Rodríguez-Pinilla MS; Manso R; Salgado-Sánchez RN; Cerdá-Montagud A; Quesada-Espinosa JF; Gómez-Rodríguez MJ; Paz-Artal E; Muñoz-Calleja C; Arranz-Sáez R; Allende LM
    J Clin Immunol; 2023 Jan; 43(1):165-180. PubMed ID: 36066697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
    Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
    Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
    Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
    Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.
    Jiang L; Luo Y; Zhu S; Wang L; Ma L; Zhang H; Shen C; Yang W; Ren Y; Zhou X; Mei C; Ye L; Xu W; Yang H; Lu C; Jin J; Tong H
    Cancer Sci; 2020 Feb; 111(2):580-591. PubMed ID: 31804030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.
    Bacher U; Weissmann S; Kohlmann A; Schindela S; Alpermann T; Schnittger S; Kern W; Haferlach T; Haferlach C
    Br J Haematol; 2012 Jan; 156(1):67-75. PubMed ID: 22017486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased CD177
    Alayed K; Meyerson HJ
    Leuk Res; 2022 Jan; 112():106752. PubMed ID: 34896936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clonal haematopoiesis: A concise review].
    Danlos FX; Papo M; Micol JB
    Rev Med Interne; 2019 Oct; 40(10):684-692. PubMed ID: 31126662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms.
    Seethy AA; Pethusamy K; Kushwaha T; Kumar G; Talukdar J; Chaubey R; Sundaram UD; Mahapatra M; Saxena R; Dhar R; Inampudi KK; Karmakar S
    BMC Cancer; 2023 Oct; 23(1):1035. PubMed ID: 37884893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Predisposition and progression of myelodysplastic syndromes].
    Makishima H
    Rinsho Ketsueki; 2021; 62(4):278-288. PubMed ID: 33967153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene mutation analysis using next-generation sequencing and its clinical significance in patients with myeloid neoplasm: A multi-center study from China.
    Li J; Pei L; Liang S; Xu S; Wang Y; Wang X; Liao Y; Zhan Q; Cheng W; Yang Z; Tang X; Zhang H; Xiao Q; Chen J; Liu L; Wang L
    Cancer Med; 2023 Apr; 12(8):9332-9350. PubMed ID: 36799265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial Acute Myeloid Leukemia and Myelodysplasia in Hungary.
    Király AP; Kállay K; Gángó A; Kellner Á; Egyed M; Szőke A; Kiss R; Vályi-Nagy I; Csomor J; Matolcsy A; Bödör C
    Pathol Oncol Res; 2018 Jan; 24(1):83-88. PubMed ID: 28357685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study.
    Cargo C; Bernard E; Beinortas T; Bolton KL; Glover P; Warren H; Payne D; Ali R; Khan A; Short M; Van Hoppe S; Smith A; Taylor J; Evans P; Papaemmanuil E; Crouch S
    Lancet Haematol; 2024 Jan; 11(1):e51-e61. PubMed ID: 38135373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms.
    Bartels S; Schipper E; Hasemeier B; Kreipe H; Lehmann U
    Oncotarget; 2016 May; 7(21):30084-93. PubMed ID: 27029036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
    Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
    Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
    [No Abstract]   [Full Text] [Related]  

  • 20. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
    Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
    Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.